Immatics N.V.
IMTX
Positions held
Your positionsIMTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Immatics N.V. is positioned in the biotechnology sector, which is experiencing rapid advancements and increasing investment, particularly in personalized medicine and immunotherapy.
- Revenue increased by 20% compared to the prior quarter, reaching $9.1 million.
- The current ratio stands at 7.536, indicating strong liquidity and ability to cover short-term obligations.
- The company's operating margin is significantly negative at -735%, reflecting ongoing financial challenges.
- Immatics has a market capitalization of approximately $1.14 billion, but its forward P/E ratio is -3.63, indicating potential concerns about future earnings.
- The stock has a 'Strong Sell' signal with a score of -24.00, driven by negative trends and technical indicators.
Fundamentals
| Market cap | $1.12B | Enterprise value | $628.66M | Trailing P/E | — | Forward P/E | -3.57 |
| PEG | — | Price / book | 2.24 | Beta | 1.36 | Dividend yield | 0.00% |
| Revenue growth | 93.0% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -7.3% |
| Profit margin | 0.0% | ROE | -47.8% | ROA | -26.9% | Debt / equity | 0.04 |
| Current ratio | 7.54 | Free cash flow | -$126.54M | Analyst recommendation | none | Mean target | $17.63 |
| 52w high | $12.41 | 52w low | $7.02 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $9.1M | $7.6M | $19.8M | $5.2M | $4.7M | — |
| Op margin | -735.0% | -867.9% | -196.8% | -1053.3% | -1121.5% | — |
| Net income | -$62.5M | -$57.8M | -$35.7M | -$50.5M | -$70.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$67.2M | -$66.1M | -$38.9M | -$54.6M | -$53.1M | — |
- Revenue +20% vs prior quarter ($9.1M vs $7.6M).
- Operating margin expanded to -735%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $48.3M | $156M | $54.0M | $173M | — |
| Op margin | -377.1% | -24.8% | -188.4% | 17.3% | — |
| Net income | -$196M | $15.2M | -$94.6M | $27.7M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$182M | -$38.6M | -$102M | $30.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Nanobiotix Appoints Arnd Christ as CFO
2026-09-04 · Immatics and 4 More Stocks See Action From Activist Investors
2026-08-25 · Sector Update: Healthcare Stocks Advance Tuesday Afternoon
2026-08-25 · Sector Update: Healthcare Stocks Edge Higher Premarket Tuesday
2026-08-25 · Sector Update: Healthcare
2026-08-25 · Immatics Announces $150 Million Underwritten Offering
2026-08-25 · Immatics Announces $150 Million Underwritten Offering
2026-08-20 · Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets
2026-08-18 · Sector Update: Healthcare Stocks Flat to Higher Premarket Tuesday
2026-08-18 · Immatics' Q2 Net Loss Narrows as Revenue Rises
2026-08-18 · Immatics: Q2 Earnings Snapshot
2026-08-18 · Immatics Announces Second Quarter 2026 Financial Results and Business Update
Price (daily)
Full chart · RSI · MACD · patterns